Hydrocodone combination products to become Schedule II drugs
September 15, 2014
On October 6, new Drug Enforcement Administration (DEA) requirements will be in place for all hydrocodone-containing products (HCPs). See DEA’s Final Rule for more details. Specifically, all HCPs will be Schedule II drugs, whereas at the present time, some are Schedule II, while others are Schedule III drugs. Hydrocodone is used at times in canine medicine for its ability to help control coughing in dogs and for pain control, so the scheduling change could be particularly of interest to small animal veterinarians.